Yohann Loriot

Yohann Loriot is a leading European urothelial cancer researcher who led the BLC2001 trial demonstrating efficacy of erdafitinib, the first targeted therapy approved for urothelial carcinoma with FGFR2/3 alterations. He has contributed extensively to antibody-drug conjugate clinical development in bladder cancer and has been involved in multiple landmark trials changing urothelial cancer treatment. His research encompasses biomarker identification, resistance mechanisms, and combination strategies in advanced bladder cancer. He is among the most influential young investigators in European GU oncology.